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Abstract
Centronuclear myopathies (CNM) are inherited congenital disorders characterized by an excessive number of internalized
nuclei. In humans, CNM results from ,70 mutations in three major genes from the myotubularin, dynamin and
amphiphysin families. Analysis of animal models with altered expression of these genes revealed common defects in all
forms of CNM, paving the way for unified pathogenic and therapeutic mechanisms. Despite these efforts, some CNM cases
remain genetically unresolved. We previously identified an autosomal recessive form of CNM in French Labrador retrievers
from an experimental pedigree, and showed that a loss-of-function mutation in the protein tyrosine phosphatase-like A
(PTPLA) gene segregated with CNM. Around the world, client-owned Labrador retrievers with a similar clinical presentation
and histopathological changes in muscle biopsies have been described. We hypothesized that these Labradors share the
same PTPLAcnm mutation. Genotyping of an international panel of 7,426 Labradors led to the identification of PTPLAcnm
carriers in 13 countries. Haplotype analysis demonstrated that the PTPLAcnm allele resulted from a single and recent
mutational event that may have rapidly disseminated through the extensive use of popular sires. PTPLA-deficient Labradors
will help define the integrated role of PTPLA in the existing CNM gene network. They will be valuable complementary large
animal models to test innovative therapies in CNM.
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Introduction
In humans, myotubular/centronuclear myopathies, often re-
ferred to as CNM, are congenital inherited myopathies charac-
terized by generalized muscle weakness associated with respiratory
insufficiency, external ophthalmoplegia and normal function of the
central and peripheral nervous system. Muscle biopsies show a
type 1 fiber predominance and excessive numbers of fibers with
internalized or centralized nuclei [1,2]. Clinical presentations in
patients are very heterogeneous and in most instances, correlate
with mutations in distinct genes. The very severe X-linked form
(XLMTM, OMIM 310400) affects neonates and carries a poor
prognosis. This form is due to mutations in the myotubularin gene
(MTM1; www.hgmd.cf.ac.uk and [3]). Milder late-onset childhood
or adult-onset autosomal dominant forms (ADCNM, OMIM
160150) are mainly due to mutations in the dynamin 2 gene
(DNM2) or, in one reported case, in the ryanodine receptor gene
(RYR1) [4,5]. Intermediate autosomal recessive forms (ARCNM,
OMIM 255200) are due to mutations in the BIN1/amphiphysin 2
(BIN1), myotubularin-related 14 (MTMR14) [6,7] or RYR1 genes
[8,9]. Despite these major advances in the identification of CNM-
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causing genes in humans, 30% of sporadic or familial cases remain
genetically unresolved, underlying the existence of additional
causative genes in the CNM functional network.
Years ago, an autosomal recessive congenital canine CNM was
described in Labradors from an experimental pedigree developed
in France from two probands [10,11]. By linkage analysis, the
locus was mapped to canine chromosome 2, and an associated
mutation was identified in a gene annotated as the protein tyrosine
phosphatase-like A (PTPLA) gene. In affected dogs, the homozy-
gous genotype resulting from the insertion of a SINE within exon 2
of PTPLA correlated with a complex panel of splicing defects in
skeletal muscles, eventually leading to a 99% decrease in the
amount of wild-type PTPLA transcripts [12], compatible with a
loss-of-function mutation. For decades, phenotypically similar
myopathies have been reported in client-owned Labradors living
in the USA, the United Kingdom, Australia, Canada and Europe
[13,14,15,16,17], and have been named type II fiber deficiency
[13], autosomal recessive muscular dystrophy [18] or hereditary
myopathy of Labrador retrievers (HMLR) [19,20]. Here we
demonstrate that regardless of the country of origin, every client-
owned Labrador retriever diagnosed with any of these phenotyp-
ically similar myopathies carried the same PTPLA loss-of-function
allele first identified in our experimental pedigree. Further, our
findings provide evidence that this allele originated from a leading
founder that sustained rapid dissemination worldwide. Finally, we
show that the variable expression of disease severity in affected
dogs does not rely on genetic polymorphisms within the inserted
SINE sequence.
Results
Selection of an international panel of CNM/
Phenotypically similar Labrador retrievers
To perform a global genetic analysis on CNM/Phenotypically
similar dogs, further referred to as CNM Labradors, we set up an
initial confirmation panel of DNA from 32 client-owned
Labradors living in the USA, Germany, the UK, France and
Denmark, which had been initially diagnosed with type 2 fiber
deficiency, autosomal recessive muscular dystrophy, HMLR or
CNM (Table 1, Table 2 and Table S1). Two Labradors with a
diagnosis of myasthenia gravis or primary neuropathy were
included as controls. Although records were incomplete in some
cases, clinical signs in affected dogs included gait abnormalities,
generalized weakness, fatigability, absence of patellar reflexes, and
generalized muscle atrophy prominently affecting limb, cervical
and temporal muscles. Structural remodeling of skeletal muscles
included atrophic (#25 mm of diameter) and anguloid-round
fibers, fiber size variation, endomysial and perimysial fibrosis,
predominance of type I fibers and internalization or centralization
of nuclei in some fibers (Figure 1 and Table S1).
A unique mutation in CNM Labradors
It was previously shown that Labradors from a French
experimental pedigree segregating CNM carry two copies of the
PTPLA g.9459-9460ins238 mutation (Figure 2A; [12]). First, to
determine whether client-owned CNM Labradors from the USA
carry the same recessive disease-causing mutation, one affected
female proband from the initial confirmation panel (US-3), an
unaffected sister, parents, and a great-grandfather were genotyped
by PCR, as described [12]. DNA from the healthy sister yielded a
unique product of 610 bp, which is the size of the wild-type
PTPLA allele. In contrast, DNA from the female proband yielded a
unique product of ,850 bp, a size corresponding to the CNM-
causing allele. The two healthy parents and great-grandfather
were heterozygotes (Figure 2B).
Second, genotypes of the 32 dogs from the initial confirmation
panel were analyzed (Figure 2C and full list of results in Table S1).
We confirmed that the two control dogs were homozygous for the
wild-type allele (DE-3 and DE-5), and identified that 77% of dogs
(23/30) were homozygous for the PTPLA mutation. One was
heterozygous and six were homozygous for the wild-type allele.
The heterozygous USA dog (US-11) expressed none of the early
histopathological signs of CNM, but a type 1 predominance that
has never been observed in heterozygous dogs from the
experimental pedigree. An idiopathic etiology was favored for
this dog. Wild-type dogs were from the UK and Germany and
corresponded to orphan cases for which precise clinical or
histopathological records were missing.
A genetic test was thus proposed to owners for diagnostic or
breeding purposes (www.labradorcnm.com). In the last 7 years, we
received and genotyped samples from 7,426 Labradors living in 18
countries (Figure 3 and Table 3). In this unique comprehensive
Table 1. Number of genotyped dogs used in this study.
+/+ +/cnm cnm/cnm Total
Dogs tested for the mutation (whole panel) 6 173 1 173 80 7 426
Dogs with clinical or histopathological reports (initial confirmation panel) 5 1 26 32
Dogs included in the haplotype analysis 39 - 32 71
Dogs sequenced (SINE insertion) - - 12 12
The whole panel includes all dogs for which samples were received for testing purposes. The initial confirmation panel includes dogs with an early diagnosis of HLMR or
phenotypically similar myopathies (Table S1).
doi:10.1371/journal.pone.0046408.t001
Table 2. Numbers by genotype of Labradors diagnosed with
HMLR or phenotypically similar myopathy.
+/+ +/cnm cnm/cnm Total
US 0 1 14 15
Germany 4 0 7 11
UK 1 0 2 3
France 0 0 2 2
Denmark 0 0 1 1
Total 5 1 26 32
Countries of origin of dogs are listed. With the exception of two German
Labradors used as controls, all Labradors were genotyped because they had
initially been diagnosed with HMLR or phenotypically similar myopathies (Table
S1).
doi:10.1371/journal.pone.0046408.t002
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panel of client-owned dogs, we identified 80 dogs from six
countries that were homozygous for the mutated PTPLA allele.
Sixty-eight were young dogs that had already displayed clinical
signs of CNM and twelve were asymptomatic one-month-old pups
at the time of testing; a few weeks after testing, all pups displayed
clinical signs consistent with CNM. On the contrary, none of the
1,172 heterozygous dogs living in 13 different countries displayed
clinical signs of CNM, confirming the strict autosomal recessive
mode of inheritance of CNM in Labradors. Affected and healthy
carriers included both males and females with the three recognized
yellow, black and chocolate coat colors (Table S2 and Table S3).
Reports of clinical signs in the 80 CNM genotyped dogs or of
histopathological features in affected dogs from the initial
confirmation panel suggested a spectrum in severity of the disease
(Table S1). In the SILV/PMEL gene, the length of the oligo(dA)-
rich tail of an inserted SINE was shown to influence the merle
phenotype penetrance in dogs [21]. Thus, we visually checked the
size of the PTPLAcnm allele amplified from DNAs of the 1,172
healthy carriers from the whole panel and the 80 affected dogs
(representative panel in Figure S1). No fragment length polymor-
phisms were observed. The PTPLAcnm allele was further sequenced
in 12 CNM dogs from the initial confirmation panel and no base
pair polymorphisms were identified within SINE sequences
(Figure S2).
In light of the finding that all affected Labradors share a unique
well-conserved mutation causing muscle defects analogous to those
seen in human forms of CNM, we propose that the mutated allele,
initially named PTPLAalf [12], becomes PTPLAcnm.
Founder effect for the PTPLAcnm allele
A unique origin for the PTPLAcnm allele was suggested by
pedigree analyses showing that some affected Labradors from
Germany and France had UK champions in their background
(Table S1), where the prevalence of CNM is one of the highest
(Table 3). To confirm that all occurrences of the disease were due
to a single ancestral mutation, we constructed a series of
haplotypes with SNPs from a 9-Mb region surrounding the
PTPLA locus (Table S4 and Table S5) for each of 39 homozygous
PTPLA+/+ healthy Labradors and 32 PTPLAcnm/cnm affected
Labradors.
A thorough analysis of genotyping data revealed that 100% of
affected Labradors (n = 32) shared two copies of a common short
haplotype of 489.4 kb, extending from SNP 21763 to SNP 22253
(Figure 4, Figure S3). The A-T-G short haplotype is highly
predictive of the disease condition in the PTPLAcnm/cnm affected
dogs (P=3.87610221), and was identified at a carrier frequency of
12.8% (10/78 haplotypes) in healthy control dogs. Further
analyses indicated that a second long haplotype of 3.8 Mb and
covering 10 SNPs from SNP 20687 to SNP 24518 (G-G-A-T-A-T-
G-C-A-A), remained highly associated with the disease
(P=2.59610219). The frequency of this longer haplotype segment
in affected dogs was 77,4% (48/62 haplotypes) and was not found
in healthy dogs (0/78 haplotypes).
A hierarchical clustering analysis using genotypes obtained for
these 10 SNPs confirmed that at k = 8, all affected dogs segregated
in a single highly predictive haplogroup, regardless of their
geographic origin (Figure 5). Closer examination of this long
haplotype segment revealed that CNM dogs finely stratified into
distinct sub-groups, each diverging from the CNM haplotype by
loss of homozygosity at one or two SNPs (Figure S3). Using the
mutation-rate of 3.061028 mutations/nucleotide/generation re-
ported in humans [22], we calculated that 17.5 generations would
separate today’s Labradors from the original PTPLAcnm founder.
Figure 2. PTPLA mutation in the initial confirmation panel of
CNM dogs. (A) Wi ld-type (wt = 610 bp) and PTPLAcnm
(cnm=wt+238 bp) alleles in a healthy carrier (FR-1) and an affected
(FR-2) Labrador from the French experimental pedigree. (B) Segregation
of the PTPLAcnm allele in a four-generation pedigree of a client-owned
US proband female (arrow). (C) Genotypes of client-owned Labradors
from several countries, diagnosed with CNM-related myopathies
(asterisks; Table S1). US-6 is a champion known to have produced
CNM pups; DE-5 is a control affected by a neuropathy and FR-2 was
reloaded for size comparison.
doi:10.1371/journal.pone.0046408.g002
Figure 1. Client-owned US Labradors share similar morpho-
logical and histopathological features with French CNM dogs
from the experimental pedigree. French CNM (A–C) and US HMLR
(D–F) affected dogs have atrophic skeletal muscles, the most affected
being those of pelvic limbs (e.g. biceps femoris muscle, arrows in A,D).
B,C,E,F are Hematoxylin-Eosin-stained transverse sections of the biceps
femoris muscle from 6-month-old (B, FR-4; E, US-18) or 10-year-old (C,F)
affected Labradors. Early signs include groups of atrophic fibers,
surrounded by endomysial (e) and perimysial (p) fibrosis. In older dogs,
increased internalized or centralized nuclei (asterisks) and fatty
infiltration (f) are observed. Scale bar = 50 mm.
doi:10.1371/journal.pone.0046408.g001
Founder Effect in CNM Labradors
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e46408
Assuming a generation time of 2.5–3 years in dogs, we estimate
that the PTPLAcnm mutation arose ,50 years ago. Healthy
Labradors were later subdivided into seven haplogroups, reflecting
the genetic heterogeneity of the Labrador breed, the most popular
in the world.
Discussion
PTPLAcnm, a prevalent and fully penetrant mutation with
variable expressivity
This report shows that the PTPLAcnm allele, initially identified in
a French experimental pedigree, is the worldwide fully penetrant
allele causing CNM in client-owned Labradors. On the basis of
the results obtained in the past 24 months, we estimate that one
dog in seven is a CNM carrier (245/1,757= 13,9%), with the
highest percentages found in the UK (19%), the USA (13%) and
Canada (11,5%). A high percentage of carriers in the UK (22%)
has also been independently reported [23]. To date, the autosomal
recessive CNM is the most prevalent hereditary myopathy
segregating in Labradors.
Variable phenotypic expression of PTPLAcnm was revealed by
differences in pups’ gain of weight, age of first clinical signs or
extent of muscle atrophy and remodeling. A first hypothesis relied
on a variable PTPLA function resulting from a SINE-dependent
modulation of the splicing machinery. For example, Merle (SILVM)
is a coat color mutation that is inherited in an autosomal,
incompletely dominant fashion, with rare SILVM/+ dogs not
exhibiting the merle phenotype. These phenotypic reversions are
due to a ,30 bp shortening of the oligo(dA)-rich tail of the SINE
responsible for the SILVM mutation [21]. In CNM dogs, this
mechanism can be excluded because no polymorphisms were
detected in the inserted SINE. The variable phenotypic expression
may thus depend upon undetected functional polymorphisms yet
to be identified in PTPLA, its functionally redundant paralogs, or
additional genetic modifiers.
Identifying the origin of the PTPLAcnm allele
The Labrador breed is characterized by a 785-kb linkage
disequilibrium, the shortest in dogs [24]. The simplest explanation
Figure 3. Percentage of wild-type homozygous (+/+), healthy carriers (+/cnm) and CNM affected (cnm/cnm) Labradors tested for
medical or breeding purposes. The total number of dogs for each period is indicated above histograms. Additional dog samples from Australia
(n = 15), New-Zealand (n = 2), Puerto Rico (n = 1) and Argentina (n = 1) were tested; they were all homozygous for the wild-type allele (+/+).
doi:10.1371/journal.pone.0046408.g003
Table 3. Numbers by genotype of Labradors tested for medical or breeding purposes.
2005–2007 2008–2009 2010–2012
+/+ +/cnm cnm/cnm +/+ +/cnm cnm/cnm +/+ +/cnm cnm/cnm Total
US 1 954 400 32 1 575 302 19 1 195 186 9 5 672
– carriers 16,8% 15,9% 13,4%
Canada 155 22 0 103 14 1 104 13 2 414
– carriers 12,4% 11,9% 10,9%
UK & Ireland 10 5 10 253 41 2 141 28 1 491
– carriers 20% 13,9% 16,5%
Continental Europe 140 71 4 324 50 0 201 40 0 830
– carriers 33% 13,4% 16,6%
Others 5 0 0 7 0 0 7 0 0 19
Total 2 264 498 46 2 262 407 22 1 648 267 12 7 426
Dogs are grouped by geographical origin and period of testing. The percentage of healthy carriers (+/cnm), suggestive of the PTPLAcnm allele segregation in Labrador
lines, is provided.
doi:10.1371/journal.pone.0046408.t003
Founder Effect in CNM Labradors
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for the presence of a long 3.8 Mb haplotype segment shared by
CNM affected dogs, is that the ancestral PTPLAcnm allele arose
recently, about 50 years ago, but sufficiently long ago for the
accumulation of de novo mutations. The large size of the CNM
haplotype and the high percentage of carriers favor a rapid
expansion of the haplotype among Labradors, suggesting that the
mutation appeared within the pedigree of a very famous stud.
Accordingly, several National Stake winners of the 1950s and the
1970s are dominant in pedigrees of contemporaneous champion
dogs [25], and the first clinical description has been reported in
1976 [13]. Absence of the associated haplotype in the tested
healthy population highly suggests that this champion emerged
from a marginal line of Labradors, or resulted from introduction of
genetic diversity from other breeds.
CNM Labradors, a model in comparative
pathophysiology and therapeutics
A global therapeutic strategy for this heterogeneous group of
CNM may be economically relevant and to reach this goal, it is
essential to understand how the different CNM-causing genes,
including PTPLA, interact to build a functional muscle and to
maintain its homeostasis. A collection of animal models with loss-
or gain-of-function mutations in CNM-causing genes has been
developed. They have been instrumental in identifying common
defects in membrane organization, trafficking or remodeling
(reviewed in [26,27]), mimicking structural aberrations observed
in muscle biopsies from BIN1, MTM1, and DNM2-CNM patients
[28,29]. In humans and CNM animal models, altered triad
junctional complexes have been observed, suggesting deficient
intracellular Ca2+ homeostasis and impaired excitation-contrac-
tion coupling [28,30,31,32,33]. A plausible mechanism is that
DNM2 at the Z-disk would play a role in the transverse orientation
of T-tubules through its interaction with BIN1, localized at the T-
tubule [34]; the concomitant recruitment of DNM2 and BIN1,
two phosphoinositide-binding proteins, would be tightly regulated
by the phospahtidylinositol (PtdIns) 3-phosphatase activity of
MTM1 and MTMR14 [7,35]. Once established, excitation-
contraction complexes would be maintained and functionally
regulated by CNM genes. Indeed deregulation of the Ca2+
handling in adult CNM muscles have been attributed to increased
PtdIns(3,5)P2 levels on the activity of the RYR1 Ca2+ sarcoplasmic
channel [32], or to a PtdIns-independent consequence of MTM1
deficiency on mitochondrial positioning and homeostasis [29].
Abnormal membrane traffic at the neuromuscular junction has
also been shown in MTM patients [36] and mice models [37].
Finally, it has been shown that deficiency of MTMR14 alone, or in
combination with MTM1, promotes autophagy initiation through
increased levels of PtdIns3P, thereby suggesting that the CNM
pathomechanism is complex and may combine regulation of
intracellular Ca2+ homeostasis, neuromuscular junction efficiency
and autophagy.
PTPLA is a 3-hydroxyacyl-CoA dehydratase (HACD), which is
an endoplasmic reticulum resident enzyme that catalyzes the third
reaction of elongation of very long chain fatty acids (VLCFA)
[38,39]. Saturated and monounsaturated VLCFA are components
of sphingolipids, a large family of lipids that are enriched in lipid
rafts and display crucial structural and signaling roles [40].
Directly or following their inclusion into sphingolipids and
phosphoinositides, VLCFA may participate in muscle homeostasis
by targeting phosphoinositides to specific cellular compartments or
by regulating their levels. Indeed deficiency in the yeast PTPLA
ortholog (Phs1) decreases the amount of VLCFA and correspond-
ing sphingolipids and indirectly reduces the level of some
phosphoinositides [38,41]. A complementary role of VLCFA
may be to promote the clustering of neuromuscular junction
components and signaling complexes in lipid rafts. In-depth
Figure 4. A 3.8-Mb haplotype is highly associated with CNM. The acrocentric region of the PTPLA locus within canine chromosome 2 (CFA2) is
depicted. Positions of genotyped SNPs are indicated. The short and long haplotypes associated with CNM are shown in green and red, respectively.
For each SNP, the allele detected in the CNM associated haplotype is indicated and represented as a grey box. The alternative allele is represented as
a white box. For each SNP, the minor allele frequency (MAF) in the healthy population of Labradors is given. The PTPLAcnm allele is represented by a
black dot (N) and the wild-type PTPLA+ allele by a ‘‘+’’. Frequencies of long 3.8-Mb haplotypes in each population of CNM or healthy dogs are given
below each haplotype. For haplotypes with frequencies .10%, width of haplotypes is proportional to its frequency. Haplotypes with frequencies
below 3% have been omitted and are detailed in Figure S3.
doi:10.1371/journal.pone.0046408.g004
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analysis of PTPLA-deficient animals will help precisely understand
the role of VLCFA in the functional network of other CNM genes.
Ultimately, CNM Labradors will be a relevant large animal model
for inclusion in pre-clinical trials of innovative drugs and gene or
cell therapies.
Materials and Methods
Dogs Included in the Study
A total of 7,426 Labrador retrievers from 19 countries were
included in the study (whole panel, Table 1). A subgroup of the
whole panel was named the ‘‘international confirmation panel’’. It
was composed of 32 dogs from the US, Germany, UK, Denmark
and France for which clinical, histopathological or genetic reports
were provided (Table 2, Table S1). Haplotype analyses were
conducted on a representative group of 71 healthy (wild-type, +/+)
or affected (CNM, cnm/cnm) Labradors from 9 countries. Each dog
was assigned a unique identifier made of a 2-letter code for its
country of origin, followed by an incremental number (e.g. UK-3).
Ethics statement
All but one dog, FR-2, were examined with the consent of their
owners. Blood and biopsies were obtained as part of routine
clinical procedures for diagnostic purposes. Cheek cells were
collected by owners or veterinarians using non-invasive swabs. As
the data were from client-owned dogs undergoing normal
veterinary exams, there was no ‘‘animal experiment’’ according
to the legal definitions in France, Germany, Denmark, the US and
the UK. All local regulations related to clinical procedures were
observed.
FR-2 was a founder dog of our experimental pedigree, and
materials from FR-2 used in this study were frozen samples
obtained in the 1990s by one of the co-authors (SB). At the time
FR-2 was sampled, there was no animal welfare committee at the
Ecole nationale ve´te´rinaire d’Alfort; however, SB was accredited
by the Veterinary Division of the French Ministry of Agriculture to
perform research on animals.
Figure 5. Hierarchical clustering from the 81 dogs at k=8. The analysis was based on genotypes obtained for ten loci (SNP 20687 to SNP
24518). Hubert Gamma values are indicated for k$2 on the top left panel. The scale on the right axis represents the genetics distances calculated by
PLINK software. In the dendogram, each vertical line represents a dog and colors reflect the eight clusters obtained by the analysis. Grey dash lines
indicate common ancestors inferred from the analysis. Below the dendogram, dogs are named by their unique identifier. The ‘‘CNM_’’ prefix was
added to the name of affected Labradors.
doi:10.1371/journal.pone.0046408.g005
Founder Effect in CNM Labradors
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DNA Extraction and SINE Sequence Analysis
Genomic DNA was extracted either from blood using a
proteinase K digestion followed by a classical phenol/chloroform
purification or from cheek swabs using the ChargeSwitch gDNA
buccal cell kit following manufacturer’s instructions (Invitrogen).
SINE amplification by PCR was carried out as previously
described [12], using the following primers: 59-CCTCGAA-
GAAGGGTCAGTGTAA-39 and 59-CCAGCCACAATCACA-
GAAGTAG-39. This produced 610-bp and 848-bp amplicons
from the wild-type and mutated alleles, respectively. For a
representative panel of 12 differentially affected dogs (bold
numbers, Table S1), the mutated amplicon encompassing the
SINE was purified and sequenced (GATC, Germany). Passed
sequences were aligned using the Multalin version 5.4.1 software
(multalin.toulouse.inra.fr).
SNPs Selection and Genotyping
These experimental steps were performed as previously
described [42]. The list of the 15 selected SNPs with their
positions is provided in Table S4. Primer sequences and optimal
melting temperatures are detailed in Table S5.
Haplotype Analysis and Clustering
Haplotype phases were inferred using the program fastPHASE
version 1.4.0. Haplotype frequencies and associations were
calculated using the statistical software package PLINK (http://
pngu.mgh.harvard.edu/purcell/plink) (v1.07). Clustering analyses
were performed using PLINK to compute the IBS distance
matrice, and hierarchical clustering using the R function Hclust
(http://cran.r-project.org/). Both PLINK and HCLUST use
distance matrix to perform clustering. For HCLUST, we used a
method that merged clusters based on a point biserial correlation
with the Hubert Gamma statistics, that measures the correlation
between groupings and distances.
Supporting Information
Figure S1 Size conservation of the SINE insertion in 25
unrelated affected Labradors. Dogs were from the US (US;
n = 20), the UK (UK; n=3), Denmark (n= 1) and Canada (n = 1).
In every tested dog, a unique band of the expected size is observed
after the specific amplification of the SINE flanked by priming
regions from exon 2.
(PDF)
Figure S2 Identity of SINE sequences amplified from 12
affected Labradors. Dogs (bolded in Table S1) were from the
US (n= 7), Germany (n= 2), UK (n= 1), Denmark (n= 1) and
France (n = 1; FR-2 is a founder dog of our experimental
pedigree). The SINE sequence is shown in red, inserted within
exon 2 of the PTPLA gene, which partial sequence is shown in
green. The two 13-bp repeat sequences flanking the SINE are
included in light-grey boxes.
(PDF)
Figure S3 Haplotypes of 71 Labradors in a 9-Mb region
around the PTPLA locus. SNP positions (in kbp) from the
centromeric to the telomeric end of the chromosome are listed on
the left of charts. Dogs, identified by the two-letter code of their
country followed by a unique incremental number for each
country, are listed on the top of charts. For each dog, the two
haplotypes are represented using a color code. The PTPLAcnm
allele is represented by a black dot (N) and the wild-type PTPLA+
allele by a ‘‘+’’.
(PDF)
Table S1 Summarized clinical signs, histopathological
features and assigned genotypes of Labradors from the
international confirmation panel. Dogs were sorted by their
country of origin and individually identified by the two-letter code
of their country followed by a unique incremental number for each
country. The 12 dogs for which SINE sequences have been
assessed are bolded and shaded in grey. When available, the age at
which biopsies were obtained is indicated. The initial diagnosis
made by co-authors, who are qualified veterinarians (NO, JP, SB)
or pathologists (GDS, TB), is reminded. When available,
informative data excerpted from their pedigree are provided. In
the last column, the assigned genotype at the PTPLA locus is given.
Abbreviations: AF, Atrophic fibers; ARF, Anguloid-Round fibers;
FatI, Fatty infiltration; FSV, Fiber size variation; GA, Gait
abnormalities; InternN, Internalized nuclei; HypoT, hypotrophy;
NF, Necrotic myofibers; NonInf, Non inflammatory; NR, Nema-
line rods; no PR, no patellar reflex; type 1P, type 1 fiber
predominance; WK, Weakness.
(PDF)
Table S2 Numbers by genotype and sex of Labradors
tested for medical or breeding purposes. The period of
testing was 2005–2012.
(PDF)
Table S3 Numbers by genotype and coat colors of
Labradors tested for medical or breeding purposes.
The period of testing was 2005–2012.
(PDF)
Table S4 Positional information for the 15 polymorphic
SNPs from CFA2 used in the haplotype analysis. Their
names and position, from the centromere of CFA2, are indicated
in the two first columns. The first group from BICF2P407690 to
BICF2P583542 encompasses the ,4.2 Mb centromeric region of
PTPLA. The second group from BICF2P642478 to
BICF2S23249211 encompasses the ,4.8 Mb telomeric region of
PTPLA.
(PDF)
Table S5 Experimental conditions to amplify the 15
polymorphic SNPs from CFA2 used in the haplotype
analysis. Primers listed were used to amplify the sequence
(Forward and Reverse primers) and to identify the SNP
(Sequencing primer).
(PDF)
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